Submit

Login Login

Register Register

Home / Journals / CJU / Vol.19, Suppl.5, 2012
Journal Menu
Special Issues
Table of Content

All issues

Online First

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

1995

Past Issues

Show export options

  • Open AccessOpen Access

    EDITORIAL

    Re-Claim the Condition: The Shifting Roles of PCPs and Urologists

    Jack Barkin
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 1-1, 2012
    Abstract This article has no abstract. More >

    View

    95

    Download

    87

  • Open AccessOpen Access

    ARTICLE

    Medical management of overactive bladder

    Sidney B. Radomski1, Jack Barkin2
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 2-9, 2012
    Abstract Overactive bladder (OAB) with or without urinary incontinence is a common condition in both men and women. OAB has a signifcant impact on quality of life for most patients. In most cases, sophisticated testing is not required for a primary care physician to diagnose OAB and start treating a patient. Management of OAB requires behavioral modifcation and, if necessary, pharmacotherapy may be added. If a patient does not respond to treatment initiated by a primary care physician, then he or she should be referred to a specialist in OAB to undergo further investigations and treatments. More >

    View

    89

    Download

    73

  • Open AccessOpen Access

    ARTICLE

    Benign prostatic hyperplasia (BPH) management in the primary care setting

    Anil Kapoor
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 10-17, 2012
    Abstract Benign prostate hyperplasia (BPH) occurs in up to 50% of men by age 50, and the incidence increases with age. This common clinical problem is diagnosed by history, including the International Prostate Symptom Score (IPSS) questionnaire, and physical examination by digital rectal examination (DRE).
    Initial management for BPH includes lifestyle modification, and smooth muscle relaxant alpha blocker therapy. Alpha blockers usually take effect quickly within 3-5 days, and have minimal side effects. Current commonly used alpha blockers include the selective alpha blockers tamsulosin (Flomax), alfusosin (Xatral), and silodosin (Rapaflo). For patients with larger prostates, the… More >

    View

    110

    Download

    93

  • Open AccessOpen Access

    ARTICLE

    Erectile dysfunction and testosterone deficiency syndrome: the “portal to men’s health”

    Michael B. Greenspan1, Jack Barkin2
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 18-27, 2012
    Abstract Erectile dysfunction (ED) and testosterone deficiency syndrome (TDS) are closely related. In addition to affecting men’s sexual health, both conditions also affect other male health issues. Screening for ED, especially in younger men, should become standard clinical practice for the primary care physician. Possible systemic effects and associated effects of TDS are now well documented. Testosterone replacement therapy (TRT) is very safe and effective in the right man. More >

    View

    102

    Download

    84

  • Open AccessOpen Access

    ARTICLE

    PSA implications and medical management of prostate cancer for the primary care physician

    Sabeer Rehsia, Bobby Shayegan
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 28-35, 2012
    Abstract Prostate cancer remains a common cancer diagnosis and cause of cancer-related death in men. Despite it’s high prevalence, screening for prostate cancer for early detection remains controversial. This article outlines evidence from contemporary prostate cancer screening clinical trials and presents an overview of therapeutic options across the spectrum of prostate-cancer states. More >

    View

    118

    Download

    121

  • Open AccessOpen Access

    ARTICLE

    What is significant hematuria for the primary care physician?

    Roland I. Sing, Rajiv K. Singal
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 36-41, 2012
    Abstract Hematuria is a common finding in primary care practice. Causes of significant hematuria include urinary tract infection, urolithiasis, malignancies, benign prostatic hyperplasia, and nephropathies. Hematuria is identified by taking a patient history and by performing a routine urine dipstick test. If a patient has a history of gross hematuria and/or a positive urine dipstick test, he or she should then have a microscopic urinalysis. The primary care physician can order ancillary tests such as laboratory tests to assess renal function, and possible imaging tests such as ultrasound, computed tomography urography, or magnetic resonance urography. The More >

    View

    101

    Download

    92

  • Open AccessOpen Access

    ARTICLE

    Diagnosis and management of simple and complicated urinary tract infections (UTIs)

    Tony Mazzulli1,2
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 42-48, 2012
    Abstract Urinary tract infections (UTIs) remain a common clinical problem in both the community and healthcare-associated settings. Each patient should be carefully assessed to ensure that a correct diagnosis is made and that antimicrobial therapy is appropriately prescribed—defined as using a clinically indicated agent in the correct dose and route of administration, for the correct duration—for symptomatic patients, and avoided for most asymptomatic patients. This should help stem the growing tide of antimicrobial resistance and allow for the continued use of simpler, less expensive agents. Continued surveillance and monitoring of antimicrobial resistance rates will be critical More >

    View

    132

    Download

    93

  • Open AccessOpen Access

    ARTICLE

    Emerging therapies: what’s new is old and what’s old is new

    Jack Barkin1, Christine Folia2
    Canadian Journal of Urology, Vol.19, Suppl.5, pp. 49-53, 2012
    Abstract Researchers are constantly seeking ways to improve existing drugs, drug mechanisms of activity, find new indications for old drugs or to develop new drugs to treat urological diseases and conditions. In Canada, tadalafil in a 5 mg daily dosage (old drug), and a new drug, silodosin, have recently become available to treat patients who have benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS). In clinical studies, silodosin has shown promise as a treatment for ureteral stones, whereas it has shown conflicting results as a potential treatment for prostatitis. Two new therapies have emerged More >

    View

    117

    Download

    76

Per Page:
Copyright© 2025 Tech Science Press
© 1997-2025 TSP (Henderson, USA) unless otherwise stated

Share Link